In addition to mutations in the receptor itself, also mutations in the tyrosine kinase JAK3 are frequent in T-ALL [2, 4, 5], while JAK1 activating mutations occur at a low frequency in T or B ALL (Fig. 1) [2, 6]. This evidence concerns the gene JAK1 and acute lymphoblastic leukemia.